Related references
Note: Only part of the references are listed.Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells
J. Joseph Melenhorst et al.
NATURE (2022)
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
Eric Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial
Olivier Tournilhac et al.
HAEMATOLOGICA (2021)
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
Thomas E. Lew et al.
BLOOD ADVANCES (2021)
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Anthony R. Mato et al.
CLINICAL CANCER RESEARCH (2020)
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E. Roeker et al.
BLOOD ADVANCES (2020)
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia
Haesook T. Kim et al.
BLOOD ADVANCES (2020)
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Valentina Griggio et al.
FRONTIERS IN IMMUNOLOGY (2020)
Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis
Almuth Hoffmann et al.
HAEMATOLOGICA (2019)
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
Peter Dreger et al.
BLOOD (2018)
Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
Michel van Gelder et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
Isabelle Kraemer et al.
BLOOD (2017)
Current state of hematopoietic cell transplantation in CLL as smart therapies emerge
Mohamed A. Kharfan-Dabaja et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)